EUVIMEDEUVIMED entdecken
Crossref

In Vitro Study of Antitumor Activity of Alogliptin in Lung Cancer Cell Line (A549)

Safa Alkhayyat, Ahsan F. Bairam

Iranian Journal of Veterinary Medicine · 01.03.2026 · 20 (2) · 359-374

DOI: 10.32598/ijvm.20.2.1005823 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Iranian Journal of Veterinary Medicine, online erschienen am 01.03.2026. Verfasst von Safa Alkhayyat und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancer is still the leading cause of cancer-related deaths globally. However, many conventional treatments are associated with high toxicity and limited selectivity for cancer cells. This condition highlights the urgent need for novel therapeutic agents with enhanced anticancer potential and reduced adverse effects on healthy tissues. Dipeptidyl peptidase-4 (DPP4) inhibitors have emerged as promising candidates for various malignancies, including colorectal, prostate, and renal cancers, due to their remarkable anticancer properties.

Objectives

This study evaluated the cytotoxic and anticancer activity of alogliptin (Alo), a selective DPP4 inhibitor, against the human lung cancer A549 cell line and normal breast epithelial HBL100 cells, as monotherapy and in combination with cisplatin (Cis).

Methods

Each type of cell (A549 cell and normal HBL100 cell) was divided into four groups: untreated control, Cis-treated, Alo-treated, and Cis+Alo-treated. After 72 hours of incubation, cell viability was assessed using the MTT (3-[4,5-dimethylthiazol-2-yl] -2,5-diphenyl tetrazolium bromide) assay to determine the half-maximal inhibitory concentration (IC50). This method is safe, more reproducible, and uses test cell viability and cytotoxicity endpoints. Following IC50-based treatment, apoptotic markers, including BCL2 and survivin expression levels, were evaluated.

Results

MTT assay showed that both Cis and Alo significantly decreased A549 cell viability (P

Zitieren

APA

Alkhayyat, S., & Bairam, A. F. (2026). In Vitro Study of Antitumor Activity of Alogliptin in Lung Cancer Cell Line (A549). Iranian Journal of Veterinary Medicine, 20(2), 359-374. https://doi.org/10.32598/ijvm.20.2.1005823

Vancouver

Alkhayyat S, Bairam AF. In Vitro Study of Antitumor Activity of Alogliptin in Lung Cancer Cell Line (A549). Iranian Journal of Veterinary Medicine. 2026;20(2):359-374. doi:10.32598/ijvm.20.2.1005823

BibTeX
@article{Alkhayyat2026,
  author = {Alkhayyat, Safa and Bairam, Ahsan F.},
  title = {In Vitro Study of Antitumor Activity of Alogliptin in Lung Cancer Cell Line (A549)},
  journal = {Iranian Journal of Veterinary Medicine},
  year = {2026},
  volume = {20},
  number = {2},
  pages = {359--374},
  doi = {10.32598/ijvm.20.2.1005823}
}
Kostenlos starten →